Lonza Produces Vaxcyte Vaccine Candidates in Visp
Published: Monday, Oct 16th 2023, 13:50
Back to Live Feed
Lonza has won another customer for its biopharmaceutical production complex "Ibex" in Visp. The pharmaceutical supplier is collaborating with US-based company Vaxcyte to develop vaccine candidates against pneumococcal diseases. The agreement includes potential global commercialisation of the candidates VAX-24 and VAX-31. Lonza will provide Vaxcyte with a "tailor-made" manufacturing suite. Construction of the facility is nearly complete and installation of the equipment will begin in 2024. Upon reaching peak capacity, Lonza will create up to 300 new jobs. Financial details of the agreement were not disclosed. This is the second contract Lonza has won in Visp after losing the coronavirus vaccine production for US-based company Moderna. Earlier in October, the company extended its collaboration with an existing customer in the area of antibody-drug conjugates (ADC), creating around 180 jobs.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic